We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

35 hedge funds and large institutions have $23M invested in Cymabay Therapeutics in 2015 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 2 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

450% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 2

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

86% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 7

27% more capital invested

Capital invested by funds: $18.2M → $23M (+$4.81M)

21% more funds holding

Funds holding: 29 → 35 (+6)

Holders
35
Holders Change
+6
Holders Change %
+20.69%
% of All Funds
0.98%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.08%
New
13
Increased
11
Reduced
2
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
A
Abingworth
United Kingdom
+$4.36M
2
KCM
Kingdon Capital Management
New York
+$2.59M
3
AC
Armistice Capital
New York
+$2.28M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$1.91M
5
OFM
Omega Fund Management
Massachusetts
+$1.77M

Top Sellers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
-$2.31M
2
EAM
EverPoint Asset Management
Connecticut
-$1.26M
3
VAM
Visium Asset Management
New York
-$626K
4
ARTA
A.R.T. Advisors
New York
-$97K
5
PP
PDT Partners
New York
-$75K
Name Holding Trade Value Shares
Change 		Change in
Stake
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$3.3M +$1.91M +700,000 +70%
A
2
Abingworth
United Kingdom
$3.07M +$4.36M +1,600,000 New
LOAMU
3
Lombard Odier Asset Management (USA)
New York
$2.13M +$969K +356,072 +48%
VVM
4
Versant Venture Management
California
$2.03M – – –
Point72 Asset Management
5
Point72 Asset Management
Connecticut
$2.01M +$1.23M +450,000 +77%
KCM
6
Kingdon Capital Management
New York
$1.84M +$2.59M +950,000 New
AC
7
Armistice Capital
New York
$1.62M +$2.28M +836,000 New
OFM
8
Omega Fund Management
Massachusetts
$1.26M +$1.77M +650,000 New
Vanguard Group
9
Vanguard Group
Pennsylvania
$830K +$260K +95,600 +29%
GTC
10
Ghost Tree Capital
New York
$776K +$1.09M +400,000 New
JGC
11
J. Goldman & Co
New York
$697K +$979K +359,500 New
VAM
12
Visium Asset Management
New York
$623K -$626K -229,790 -42%
SM
13
Sabby Management
Florida
$569K +$526K +193,294 +193%
IHM
14
Iguana Healthcare Management
New York
$485K +$27.2K +10,000 +4%
AllianceBernstein
15
AllianceBernstein
Tennessee
$456K – – –
PVI
16
Pura Vida Investments
New York
$388K – – –
Geode Capital Management
17
Geode Capital Management
Massachusetts
$166K +$100K +36,774 +75%
BNP Paribas Financial Markets
18
BNP Paribas Financial Markets
France
$107K +$27.2K +10,000 +22%
BFA
19
BlackRock Fund Advisors
California
$101K +$38.6K +14,180 +37%
BIT
20
BlackRock Institutional Trust
California
$90K – – –
Northern Trust
21
Northern Trust
Illinois
$58K +$41.2K +15,130 +101%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$58K +$81.3K +29,875 New
Parallax Volatility Advisers
23
Parallax Volatility Advisers
California
$45K – – –
VKH
24
Virtu KCG Holdings
New York
$44K +$61.6K +22,640 New
BFM
25
Boothbay Fund Management
New York
$42K +$59.6K +21,897 New
1
2

CBAY Hedge Fund Activity: Q3 2015 in Review

35 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q3 2015, worth a combined $23M — up 27% from $18.2M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new CBAY positions and 7 closed out — a net gain of 6 holders — while 11 added to existing stakes and 2 trimmed.

The largest buyer was Abingworth, opening a new position worth an estimated $4.36M. The largest seller was Jennison Associates, exiting entirely with an estimated $2.31M sold.

  • 35 institutional investors held Cymabay Therapeutics (CBAY) as of Q3 2015, up from 29 in Q2 2015.
  • Funds reported $23M of Cymabay Therapeutics stock for Q3 2015, up 27% quarter-over-quarter.
  • 13 funds opened new Cymabay Therapeutics positions in Q3 2015 and 7 closed out, a net change of +6 holders.
  • The largest Cymabay Therapeutics buyer in Q3 2015 was Abingworth, an estimated $4.36M added.
  • The largest Cymabay Therapeutics seller in Q3 2015 was Jennison Associates, an estimated $2.31M sold.

Based on aggregated 13F filings for Q3 2015.